Icon to close the modal
Support
Sales
Phone Icon
1.844.8.BD.LIFE (1.844.823.5433)
Modal Close Icon
Sales Form
Please fill out the form and a sales representative will get in touch with you.

Capability:

Product Line:

Icon to close thank you modal
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Ordering
Phone Icon
1.844.8.BD.LIFE (1.844.823.5433)
Onsite Visiting
Location Icon
850 W Rio Salado Pkwy, Tempe, AZ 85281 United States
Customer Service
Phone Icon
1.844.8.BD.LIFE (1.844.823.5433)
6:00 a.m. – 4:30 p.m. Arizona Time (Monday-Friday)
Fax Icon
1.800.440.5376
LifeStent™ and LifeStent™ XL Vascular Stent System
Contact Us navigation arrow
Background Image
Loading
tabs dropdown arrow
Overview

The LifeStent™ Vascular Stent System has achieved lasting results over the long term, with sustained effectiveness up to three years, and treatment superiority over balloon angioplasty. As the only commercially available bare metal stent FDA-approved for the superficial femoral and popliteal arteries, the LifeStent™ Vascular Stent has a history of proven performance. With its unique helical design, it is engineered for bending, compression, and torsion with dynamic vessel conformability. The LifeStent™ Vascular Stent Systems, in varying sizes, have been studied in more than ten clinical trials in the United States and globally.

The LifeStent™ Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 – 6.5mm. The LifeStent™ Vascular Stent is the only FDA-approved stent for the SFA and full popliteal artery. The LifeStent™ Vascular Stent is available in 5 mm, 6 mm, and 7 mm diameters; and 20 mm to 170 mm in length.

Additionally, the LifeStent™ Solo™ Vascular Stent is available in 6 mm and 7 mm diameters and 200 mm in length.

true
Features and Benefits
FDA-approved for the SFA and full popliteal artery
Longest lesion length indication (up to 240 mm)1
Unique helical design
Engineered for bending, compression, torsion
Dynamic vessel conformability
Improved lesion coverage with a single stent
Reference

1. As of December 2020

2. Laird et al. Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial. J Endovasc Ther. 2012;19:1-9. The LifeStent® 5 mm diameter was not included in this trial.

3. RESILIENT I Trial, RESILIENT II Trial, E-TAGIUSS Trial, Retrospective Analysis of LifeStent® Vascular Stent Systems in the Treatment of Long-Segment Lesions, LifeStent® Vascular Stent Delivery System Study (LifeStent® 200 mm Trial),REALITY I Trial,REALITY II Trial, ETAP Trial, CONTINUUM Trial, and RELIABLE Trial. Additional trials ongoing.

Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.

true

BD-23530

Products & Accessories
RELATED PRODUCTS NOT AVAILABLE
References

1. As of December 2020

2. Laird et al. Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial. J Endovasc Ther. 2012;19:1-9. The LifeStent® 5 mm diameter was not included in this trial.

3. RESILIENT I Trial, RESILIENT II Trial, E-TAGIUSS Trial, Retrospective Analysis of LifeStent® Vascular Stent Systems in the Treatment of Long-Segment Lesions, LifeStent® Vascular Stent Delivery System Study (LifeStent® 200 mm Trial),REALITY I Trial,REALITY II Trial, ETAP Trial, CONTINUUM Trial, and RELIABLE Trial. Additional trials ongoing.

Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.

true
Resources
References

1. As of December 2020

2. Laird et al. Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial. J Endovasc Ther. 2012;19:1-9. The LifeStent® 5 mm diameter was not included in this trial.

3. RESILIENT I Trial, RESILIENT II Trial, E-TAGIUSS Trial, Retrospective Analysis of LifeStent® Vascular Stent Systems in the Treatment of Long-Segment Lesions, LifeStent® Vascular Stent Delivery System Study (LifeStent® 200 mm Trial),REALITY I Trial,REALITY II Trial, ETAP Trial, CONTINUUM Trial, and RELIABLE Trial. Additional trials ongoing.

Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.

true
Frequently Asked Questions
false
Chat with us
Our live chat is available between the hours of 8.30am - 5.00pm EST, Monday - Friday
×